Literature DB >> 2464644

HLA-restricted lysis of herpes simplex virus-infected monocytes and macrophages mediated by CD4+ and CD8+ T lymphocytes.

D J Torpey1, M D Lindsley, C R Rinaldo.   

Abstract

Freshly isolated human peripheral blood monocytes and in vitro monocyte-derived macrophages were infected with HSV type 1 and used as target cells in a cell-mediated cytotoxicity assay. PBMC from both HSV-immune and non-immune donors were stimulated in vitro for 5 days with UV-inactivated HSV Ag and used as effector cells. Effectors from HSV-immune donors mediated virus-specific lysis of both monocyte and macrophage targets, whereas effectors from non-immune donors failed to mediate target cell lysis. Mean virus-specific lysis of autologous monocytes was (8.5 +/- (+/- 2.0)%) compared to a threefold greater virus-specific lysis of autologous macrophages (24.7 (+/- 4.3)%). More than 70% of this lysis was mediated by CD16- T lymphocytes. Further analysis demonstrated that the majority of the lysis against autologous and allogeneic targets was HLA-DR-restricted and mediated by CD4+ CTL. However, CD8+ CTL also contributed to the lysis of autologous targets as well as allogeneic targets having a common HLA-A and/or -B determinant. The HLA-restricted cytotoxicity was virus-specific as HSV-infected, but not CMV-infected, cells were lysed. CTL-mediated lysis of HSV-infected monocytes and macrophages may be of significance in the anti-viral and immunoregulatory host response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464644

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Cytotoxic T cells against herpes simplex virus in Behçet's disease.

Authors:  K Hamzaoui; A Kahan; K Ayed; M Hamza
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 2.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Antigen presentation of herpes simplex virus by corneal epithelium--an in vitro and in vivo study.

Authors:  G T Fahy; D C Hooper; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

4.  Demonstration of MHC class II-restricted cytotoxic T lymphocytes in mice against herpes simplex virus.

Authors:  G Kolaitis; M Doymaz; B T Rouse
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

5.  CD4(+) cytotoxic T-lymphocyte activity against macrophages pulsed with bovine herpesvirus 1 polypeptides.

Authors:  C Wang; G A Splitter
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Herpes simplex virus-infected human fibroblasts are resistant to and inhibit cytotoxic T-lymphocyte activity.

Authors:  C M Posavad; K L Rosenthal
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes.

Authors:  D M Koelle; M A Tigges; R L Burke; F W Symington; S R Riddell; H Abbo; L Corey
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens.

Authors:  M A Tigges; D Koelle; K Hartog; R E Sekulovich; L Corey; R L Burke
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome.

Authors:  H Azuma; H Sakata; M Saijyou; A Okuno
Journal:  Eur J Pediatr       Date:  1993-12       Impact factor: 3.183

10.  Herpes simplex virus-specific human cytotoxic T-cell colonies expressing either gamma delta or alpha beta T-cell receptor: role of accessory molecules on HLA-unrestricted killing of virus-infected targets.

Authors:  R Maccario; P Comoli; E Percivalle; D Montagna; F Locatelli; G Gerna
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.